OncologyGfK Healthcare's Roper Global Diabetes Program Launches New U.S. Diabetes Patient Market Study
GfK Healthcare"s Roper Global Diabetes Program, the definitive global perspective on diabetes, announced today the launch of its enhanced U.S. Diabetes Patient Market Study. Through a modular approach and with tailored reporting, the study offers health care and related companies in the diabetes category access to patient data and market trends from one of the largest surveys of people with diabetes, and the only one projectable to the U.S. population.
Considered to be the authoritative of trends in the diabetes market for more than 20 years, GfK Healthcare"s Roper U.S. Diabetes Patient Market Study offers insights from diagnosed patients into patient attitudes and behaviors, key influencers for lifestyle changes and treatment options, product usage and compliance, s of care and insurance/reimbursement, diabetes control and demographics and patients" therapy progression (e.g., orals to insulin). The enhanced 2009 report, adapted to meet the evolving needs of clients seeking time and cost-efficient diabetes research solutions, offers both standard and tailored reporting deliverables, as well as additional data collection waves, enabling clients to get the specific information and insight they need to guide decision making throughout the product life cycle.
Standard deliverables include both a market overview, a cost-effective option for landscape and market trends suitable for companies new to the diabetes category or those with new products in the pipeline, and standard issue-centric reports that offer more detailed information on key topics including monitoring, insulin, insulin devices and non-insulin therapies. Customized deliverables, beneficial to companies with specific data reporting requirements or those with narrowly defined target segments, include customized reports, high-impact customized presentations and access to GfK Healthcare"s Roper Diabetes practice leader for consulting engagements.
As a further enhancement to the study, GfK Healthcare"s Roper Global Diabetes Program is now enabling clients to conduct customized research at syndicated prices by incorporating two additional waves of data collection to the traditional study. This will allow sponsors to ask proprietary questions to get further insight into switching behavior or track particular issues affecting their business - all with the benefit of repeated waves that allow the tracking of changes over time.
"In this year"s research, we"ll be watching the uptake of newer classes of medications - the DPP-4s, GLP-1s and analogue insulins, all of which are likely to attract more competition in the next few years," said David Jacobson, Roper Diabetes practice leader. "We want to see if patient needs for better control, especially post-prandial control, are being met. We also think the market needs to understand how the economy is affecting the behaviors of people with diabetes. We"re confident the changes we"re making to the Roper program will give marketers a better understanding of these and many other trends as well as more opportunities over time to track the issues impacting their brands."
About the Roper Global Diabetes Program
GfK Healthcare"s Roper Global Diabetes Program includes a series of multi-client tracking studies with diabetes patients conducted annually in the United States and biannually in Canada and Western Europe, as well as periodic studies in Eastern Europe and the Asia Pacific. The 2009 Roper U.S. Diabetes Patient Market Study provides key information on every facet of diabetes, from patient attitudes and demographics to product awareness and usage to of care and the doctor/patient relationship. The study, fielded in June 2009, is conducted via Internet surveys and phone interviews with a sample of 2,000 diagnosed diabetes patients. The two custom tracking waves will be conducted via Internet surveys with 1,000 diagnosed diabetes patients in August and October 2009.
GfK Healthcare